IL1B and Sepsis: Moreover, broad and prolonged inhibition of pro-inflammatory pathways is inevitably detrimental even in patients with chronic inflammation and CVD, as is exemplified in CV trials of IL-1 inhibitors and colchicine where the risk of serious infection and sepsis is increased (Ridker et al., 2017; Tardif et al., 2019; Tong et al., 2020).